Table 2.
Clinical and pathological parameters of the analyzed cohort.
| Variable | pRCC Type 1 PSMA- n=193 (98.0%) |
pRCC Type 1 PSMA+ n= 4 (2.0%) |
p-value | pRCC Type 2 PSMA- n=110 (100.0%) |
pRCC Type 2 PSMA+ n=0 (0%) |
p-value |
|---|---|---|---|---|---|---|
| Age [years] median (range) | 63.0 (15-86) | 66.5 (57-77) | p=.400 | 66.0 (18-85) | ||
| NE (n) | 34 | 0 | 26 | |||
| Sex | p=.816 | |||||
| Male, n (%) | 126 (65.3) | 3 (75.0) | 64 (58.2) | |||
| Female, n (%) | 32 (16.6) | 1 (25.0) | 20 (18.2) | |||
| NE, n (%) | 35 (18.1) | 0 (0.0) | 26 (23.6) | |||
| TNM Stage | p=.382 | |||||
| pT1, n (%) | 106 (54.9) | 2 (50.0) | 37 (33.6) | |||
| pT2, n (%) | 35 (18.1) | 2 (50.0) | 14 (12.7) | |||
| pT3, n (%) | 17 (8.8) | 0 (0.0) | 30 (27.3) | |||
| pT4, n (%) | 0 (0.0) | 0 (0.0) | 1 (0.9) | |||
| NE, n (%) | 35 (18.1) | 0 (0.0) | 28 (25.5) | |||
| Grade | p=.367 | |||||
| G1, n (%) | 45 (23.3) | 0 (0.0) | 9 (8.2) | |||
| G2, n (%) | 107 (55.4) | 4 (100.0) | 52 (47.3) | |||
| G3, n (%) | 4 (2.1) | 0 (0.0) | 19 (17.3) | |||
| G4, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| NE, n (%) | 37 (19.2) | 0 (0.0) | 30 (27.3) | |||
| Lymph node metastasis # | p=.751 | |||||
| N-, n (%) | 187 (94.9) | 4 (100.0) | 93 (84.5) | |||
| N+, n (%) | 6 (3.1) | 0 (0.0) | 17 (15.5) | |||
| NE, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| Distant metastasis# | p=.819 | |||||
| M-, n (%) | 153 (79.3) | 4 (100.0) | 65 (59.1) | |||
| M+, n (%) | 2 (1.0) | 0 (0.0) | 14 (12.7) | |||
| NE, n (%) | 38 (19.7) | 0 (0.0) | 31 (28.2) | |||
| Locally Advanced disease | p=.471 | |||||
| T1/T2 N0M0, n (%) | 138 (71.5) | 4 (100.0) | 48 (43.6) | |||
| T3/4 and/or N+ and/or M+, n (%) | 18 (9.3) | 0 (0.0) | 31 (28.2) | |||
| NE, n (%) | 37 (19.2) | 0 (0.0) | 31 (28.2) |
# at time of renal surgery. Legend: N- = lymph node status unknown or tumor cells absent from regional lymph nodes, N+ = regional lymph node metastasis present, NE = not evaluable.